During the last session, Corvus Pharmaceuticals Inc (NASDAQ:CRVS)’s traded shares were 0.82 million, with the beta value of the company hitting 1.13. At the end of the trading day, the stock’s price was $6.33, reflecting an intraday gain of 8.95% or $0.52. The 52-week high for the CRVS share is $6.15, that puts it up 2.84 from that peak though still a striking 83.41% gain since the share price plummeted to a 52-week low of $1.05. The company’s market capitalization is $395.94M, and the average intraday trading volume over the past 10 days was 0.34 million shares, and the average trade volume was 401.37K shares over the past three months.
Corvus Pharmaceuticals Inc (CRVS) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.50. CRVS has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.1.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Corvus Pharmaceuticals Inc (NASDAQ:CRVS) trade information
Corvus Pharmaceuticals Inc (CRVS) registered a 8.95% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 8.95% in intraday trading to $6.33, hitting a weekly high. The stock’s 5-day price performance is 12.23%, and it has moved by 23.39% in 30 days. Based on these gigs, the overall price performance for the year is 342.66%. The short interest in Corvus Pharmaceuticals Inc (NASDAQ:CRVS) is 2.15 million shares and it means that shorts have 4.15 day(s) to cover.
The consensus price target of analysts on Wall Street is $7, which implies an increase of 9.57% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $7 and $7 respectively. As a result, CRVS is trading at a discount of -10.58% off the target high and -10.58% off the low.
Corvus Pharmaceuticals Inc (CRVS) estimates and forecasts
Statistics show that Corvus Pharmaceuticals Inc has outperformed its competitors in share price, compared to the industry in which it operates. Corvus Pharmaceuticals Inc (CRVS) shares have gone up 313.73% during the last six months, with a year-to-date growth rate more than the industry average at 19.64% against 17.50. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 16.70% this quarter and then jump 21.40% in the quarter after that.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 19.89%. While earnings are projected to return 26.34% in 2024.
CRVS Dividends
Corvus Pharmaceuticals Inc is due to release its next quarterly earnings on 2024-Nov-05. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Corvus Pharmaceuticals Inc (NASDAQ:CRVS)’s Major holders
Corvus Pharmaceuticals Inc insiders own 4.02% of total outstanding shares while institutional holders control 44.19%, with the float percentage being 46.04%. ORBIMED ADVISORS LLC is the largest shareholder of the company, while 54.0 institutions own stock in it. As of 2024-06-30, the company held over 6.94 million shares (or 14.1596% of all shares), a total value of $12.64 million in shares.
The next largest institutional holding, with 6.12 million shares, is of SAMLYN CAPITAL, LLC’s that is approximately 12.4861% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $11.14 million.
